Penn study: Herb product used to lower cholesterol works no better than placebo

August 12, 2003

A natural extract often favored by health-conscious Americans as an alternative to manufactured drugs in lowering cholesterol has turned out to be no more effective than a placebo in clinical trials at the University of Pennsylvania School of Medicine. The Penn research findings on the guggulipid extract will be published in the August 13 issue of the Journal of the American Medical Association (JAMA).

"We found that the guggulipid product did not lower the level of LDL-C (low density lipoprotein cholesterol) in our trial participants, but actually raised LDL-C slightly," said Philippe O. Szapary, MD, Assistant Professor of Medicine at Penn and principal author of the study. Low-density lipoprotein can lead to heart disease by accumulating on arterial walls. It is often identified as "bad" cholesterol by researchers in order to distinguish it from high-density lipoprotein (HDL), the "good" cholesterol that keeps arteries clear.

The randomized, double-blind, eight-week study at Penn included 103 volunteers who were divided into three groups. One group was given a standard dose (1,000 mg) of guggulipid three times daily; a second group was given a high dose (2,000 mg) of the extract; and the third group was given the placebo.

"We found LDL-C increased by four percent in the standard-dose group and five percent in the high-dose group. At the same time, it decreased by five percent in the placebo group," Szapary said.

Further, "a small subset of patients taking the herb developed a rash indicating they were experiencing hypersensitivity drug reactions," Szapary said. The rash disappeared when they stopped taking the supplement.

"Our findings do not support the use of gugglipid to control LDL-C in the general population," Szapary said. "The results do strengthen our belief that dietary supplements need to be studied in a rigorous way, to test both their safety and their efficacy." He is extending his study to investigate further the effects of guggulipid on triglycerides, also called "blood fats," and inflammation, both of which appeared to be more responsive than cholesterol to the effects of the herb in the clinical study.

Guggulipid, a substance derived from one of the fabled myrrh plants of the Middle East, has a 2,600-year tradition in traditional medicine. Indian practitioners of ayuvedic medicine have used the herb in holistic regimens combining meditation, yoga and diet to treat obesity, atherosclerosis, high cholesterol and arthritis. In the Christian tradition, the bitter-tasting, fragrant myrrh, which is used in incense and perfume, was presented as a gift from the three wise men to the infant Jesus.

Szapary was assisted in the study by Megan L. Wolf, BS; LeAnne T. Bloedon, MS, RD; Andrew J. Cucchiara, PhD; Ara H. DerMarderosian, PhD; Michael D. Cirigliano, MD; and Daniel Rader, MD, all of Penn.
The study was funded by the National Center for Complementary and Alternative Medicine at the National Institutes of Health, and the Sabinsa Corporation, manufacturer of a guggulipid extract product.

Editor's note: None of the study investigators has any financial interest in the Sabinsa Corp.

This release may also be found online at:

PENN Medicine is a $2.2 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System (created in 1993 as the nation's first integrated academic health system).

Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #4 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

Penn Health System consists of four hospitals (including its flagship Hospital of the University of Pennsylvania, consistently rated one of the nation's "Honor Roll" hospitals by U.S. News & World Report), a faculty practice plan, a primary-care provider network, three multispecialty satellite facilities, and home health care and hospice.

University of Pennsylvania School of Medicine

Related Cholesterol Articles from Brightsurf:

Cholesterol's effects on cellular membranes
The findings have far-reaching implications in the general understanding of disease, the design of drug delivery methods, and many other biological applications that require specific assumptions about the role of cholesterol in cell membranes.

Autism-cholesterol link
Study identifies genetic link between cholesterol alterations and autism.

Microbes might manage your cholesterol
Researchers discover a link between human blood cholesterol levels and a gene in the microbiome that could one day help people manage their cholesterol through diet, probiotics, or entirely new types of treatment.

Experimental cholesterol-lowering drug effective at lowering bad cholesterol, study shows
Twice-yearly injections of an experimental cholesterol-lowering drug, inclisiran, were effective at reducing low-density lipoprotein (LDL) cholesterol, often called bad cholesterol, in patients already taking the maximum dose of statin drugs, according to data of the ORION-10 trial presented Saturday, Nov.

Rethinking how cholesterol is integrated into cells
Cholesterol is best known in connection with cardiovascular disease, but cholesterol is also vital for many fundamental processes in the body.

Seed oils are best for LDL cholesterol
Using a statistical technique called network meta-analysis, researchers have combined the results of dozens of studies of dietary oils to identify those with the best effect on patients' LDL cholesterol and other blood lipids.

Cholesterol leash: Key tethering protein found to transport cellular cholesterol
Cholesterol is an essential component of living organisms, but the mechanisms that transport cholesterol inside the cell are poorly understood.

New way to treat cholesterol may be on the horizon
A breakthrough discovery by scientists at Houston Methodist Research Institute could change the way we treat cholesterol.

How low should LDL cholesterol go?
New analysis shows that in a high-risk population, achieving ultra-low LDL cholesterol levels, down to <10 mg/dL, safely results in additional lowering of risk of cardiovascular events.

Does boosting 'good' cholesterol really improve your health?
A new review addresses the mysteries behind 'good' HDL cholesterol and why boosting its levels does not necessarily provide protection from cardiovascular risk for patients.

Read More: Cholesterol News and Cholesterol Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to